These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 33315881

  • 21. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
    Einarsson JT, Geborek P, Saxne T, Kapetanovic MC.
    J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
    [Abstract] [Full Text] [Related]

  • 22. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
    Kobayakawa T, Kojima T, Takahashi N, Hayashi M, Yabe Y, Kaneko A, Shioura T, Saito K, Hirano Y, Kanayama Y, Miyake H, Asai N, Funahashi K, Hirabara S, Hanabayashi M, Asai S, Ishiguro N.
    Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402
    [Abstract] [Full Text] [Related]

  • 23. Incidence of Antidrug Antibodies in Rheumatoid Arthritis Patients From Argentina Treated With Adalimumab, Etanercept, or Infliximab in a Real-World Setting.
    Maid PJ, Xavier R, Real RM, Pedersen R, Shen Q, Marshall L, Solano G, Borlenghi CE, Hidalgo RP.
    J Clin Rheumatol; 2018 Jun; 24(4):177-182. PubMed ID: 29232322
    [Abstract] [Full Text] [Related]

  • 24. Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sectional study.
    de la Torre I, Valor L, Nieto JC, Montoro M, Carreño L.
    Reumatol Clin; 2014 Jun; 10(2):101-4. PubMed ID: 24280444
    [Abstract] [Full Text] [Related]

  • 25. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis.
    Arends S, Lebbink HR, Spoorenberg A, Bungener LB, Roozendaal C, van der Veer E, Houtman PM, Griep EN, Limburg PC, Kallenberg CG, Wolbink GJ, Brouwer E.
    Clin Exp Rheumatol; 2010 Jun; 28(5):661-8. PubMed ID: 20822711
    [Abstract] [Full Text] [Related]

  • 26. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors.
    Bodio C, Grossi C, Pregnolato F, Favalli EG, Biggioggero M, Marchesoni A, Murgo A, Filippini M, Migliorini P, Caporali R, Pellerito R, Ciccia F, Sarzi-Puttini P, Perosa F, Paolazzi G, Hollan I, Bendtzen K, Meroni PL, Borghi MO.
    Autoimmun Rev; 2020 May; 19(5):102509. PubMed ID: 32173513
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis.
    Emery P, Vlahos B, Szczypa P, Thakur M, Jones HE, Woolcott J, Santos Estrella PV, Rolland C, Gibofsky A, Citera G, Sockalingam S, Marshall L.
    J Rheumatol; 2020 Apr; 47(4):493-501. PubMed ID: 31154413
    [Abstract] [Full Text] [Related]

  • 33. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.
    Fafá BP, Louzada-Junior P, Titton DC, Zandonade E, Ranza R, Laurindo I, Peçanha P, Ranzolin A, Hayata AL, Duarte A, Silveira IG, Costa I, Macieira JC, Guedes-Barbosa LS, Bertolo MB, Sauma MF, Silva MB, Freire M, Scheinberg MA, Fernandes V, Bianchi W, Miranda JR, Pinheiro GR, Carvalho HM, Brenol CV, Pereira IA, de Castro GR, de Morais JC, Oliveira SK, de Abreu MM, Toledo RA, Pinheiro MM, Vieira WP, Valim V, BIOBADABRASIL.
    Clin Rheumatol; 2015 May; 34(5):921-7. PubMed ID: 25851594
    [Abstract] [Full Text] [Related]

  • 34. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, Pascal M, Yagüe J, Cañete JD, Sanmarti R.
    Arthritis Res Ther; 2016 Jul 08; 18(1):160. PubMed ID: 27391315
    [Abstract] [Full Text] [Related]

  • 35. Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis.
    Siljehult F, Ärlestig L, Eriksson C, Rantapää-Dahlqvist S.
    Scand J Rheumatol; 2018 Sep 08; 47(5):345-350. PubMed ID: 29701536
    [Abstract] [Full Text] [Related]

  • 36. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
    Valor L, Hernández-Flórez D, de la Torre I, Llinares F, Rosas J, Yagüe J, Garrido J, Naredo E.
    Clin Exp Rheumatol; 2015 Sep 08; 33(5):617-23. PubMed ID: 26316061
    [Abstract] [Full Text] [Related]

  • 37. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.
    Gorovits B, Baltrukonis DJ, Bhattacharya I, Birchler MA, Finco D, Sikkema D, Vincent MS, Lula S, Marshall L, Hickling TP.
    Clin Exp Immunol; 2018 Jun 08; 192(3):348-365. PubMed ID: 29431871
    [Abstract] [Full Text] [Related]

  • 38. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status.
    van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, Beckmann C, Unnebrink K, Kupper H.
    Clin Rheumatol; 2008 Aug 08; 27(8):1021-8. PubMed ID: 18350329
    [Abstract] [Full Text] [Related]

  • 39. Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Ishikawa Y, Hashimoto M, Ito H, Tanaka M, Yukawa N, Fujii T, Yamamoto W, Mimori T, Terao C.
    Semin Arthritis Rheum; 2019 Oct 08; 49(2):204-210. PubMed ID: 30803720
    [Abstract] [Full Text] [Related]

  • 40. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
    Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, Meroni PL.
    Arthritis Care Res (Hoboken); 2016 Apr 08; 68(4):432-9. PubMed ID: 26556048
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.